1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C47B0047F03FE0DB85257E0300533649
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/big-data-pharma-structure-governance-big-data-utilization-across-health-outcomes-research-functions
18
19
2054.174.51.80
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Market Research, Analytics and Forecasting Analytics

Big Data in Pharma: Structure and Governance for Big Data Utilization across Health Outcomes Research Functions

ID: 5352


Features:

13 Info Graphics

19 Data Graphics

300+ Metrics

5 Narratives


Pages/Slides: 39


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Big Data in Pharma: Structure and Governance for Big Data Utilization Across Health Outcomes Research Functions"


STUDY OVERVIEW

The availability of a wealth of data across varied sources - the foundation of Big Data - has provided an opportunity for the biopharmaceutical industry to generate valuable insights for HEOR functions. However, the inherent costs and other challenges have caused the biopharmaceutical sector to embrace Big Data analytics slower than other industries.

Best Practices, LLC undertook this study to better understand the structure and governance approaches the biopharmaceutical sector is taking for Big Data utilization across Health Outcomes Research functions. In addition, the study investigates the types of Big Data studies, the most valued partnerships and the policies that companies are using as they move to a more analytically based approach to medical decisions.

KEY TOPICS

  • Types of Big Data Projects Used to Support Medical, Commercial and HEOR Decisions
  • Big Data Capabilities and Governance
  • Value Rating of Partnerships on Big Data Projects
  • Policies and Procedures Governing Big Data Activities

SAMPLE KEY METRICS
  • Do you have a centralized/dedicated group to support Big Data projects?
  • When do you expect to establish a Big Data team?
  • Functions in North America that utilize and/or lead Big Data projects
  • Who has responsibility for these 8 Big Data capabilities at your company?
  • Will your company increase its expertise for these 9 Big Data capabilities?
  • Will your company internally increase its expertise for these 9 Big Data capabilities
  • Which partners are the most valuable for Big Data projects?
  • Indicate the policies that are in place to govern Big Data activities
  • Indicate the maturity level of 9 Big Data capabilities.
  • Types of Big Data projects used to support medical decisions
  • Rank these Big Data applications by the amount of use within your organization

SAMPLE KEY FINDING
  • A majority of participants said that partnerships with payers and data aggregators were highly impactful. Health systems were also seen as valuable partners by each of the three segments.
  • Six out of ten benchmark participants use post-launch studies around health outcomes. The second most highly rated reported data type is patient reported outcomes data.
METHODOLOGY

Fifteen analytics, marketing and HEOR leaders from 13 different pharmaceutical companies participated in this study. Participants were recruited because of their presumed investment in Big Data analytics.

Industries Profiled:
Pharmaceutical; Biotech; Chemical; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Novartis; Purdue Pharma; Genentech; AstraZeneca; Baxter International; GlaxoSmithKline ; Merck; Sanofi; Boehringer Ingelheim; Daiichi Sankyo; Pfizer; Teva Pharmaceutical Industries Ltd


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.